Apricot Capital

Founded 2015

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 15
Average round size
info
The average size of a deal this fund participated in
$9M
Portfolio companies 10
Rounds per year 2.50
Lead investments 4
Key employees 2

Areas of investment

  • Biotechnology
  • Health Care
  • Medical Device
  • Medical
  • Genetics
Summary

In 2010 was created Apricot Capital, which is appeared as VC. The venture was found in North America in United States. The main department of described VC is located in the Boston.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Apricot Capital, startups are often financed by Versant Ventures, Tavistock Life Sciences, 5AM Ventures. The meaningful sponsors for the fund in investment in the same round are Zhongjin Qichen, Where Angels Fund, Walter Winshall. In the next rounds fund is usually obtained by Romulus Capital, SeedInvest, New Enterprise Associates.

The overall number of key employees were 2.

Speaking about the real fund results, this VC is 10 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually. The important activity for fund was in 2019. The top amount of exits for fund were in 2014. Comparing to the other companies, this Apricot Capital performs on 11 percentage points more the average number of lead investments.

The fund has specific favorite in a number of founders of portfolio startups. Among the most successful fund investment fields, there are Education, Mobile. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Bellen, Placester, Ambrx For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Lena Street United States, Chicago
MIQ China, Hangzhou
RLJ Equity Partners United States, Bethesda
National City Equity Partners United States, Cleveland
MKS Switzerland, Geneva
Granot Ventures Israel, Tel Aviv
Company Ventures United States, New York
Canon BioMedical United States, Melville
Geshang Licai China, Beijing
Japan Industrial Partners Japan, Tokyo
100+ Accelerator United States, New York
Wee Hur Holdings Russia, Moscow
Good Company Israel, Tel Aviv
Tradecraft Capital United States, Austin
Sprig Investment LLC -
Xizang Zhengji Jijin Guanli -
Waverly Capital -
Trident -
Canopy San Diego United States, San Diego
GINcapital Mexico, Naucalpan de Juárez
RLJ Equity Partners -

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

GRIT Biotechnology

Biotechnology
Health Care
Medical Device
1
14 Jul 2021 China, Shanghai

Forerunner Medical

Biotechnology
Manufacturing
Medical
Medical Device
1
$15M05 Mar 2021 China, Shanghai

Medilink Therapeutics

Biotechnology
Genetics
Therapeutics
1
$50M01 Mar 2021 China, Gusu District

Jabrehoo Med Tech

Biotechnology
Genetics
Health Care
1
$15M10 Aug 2020 China, Dongcheng District

Immvira

Clinical Trials
1
$58M15 Jun 2020 China, Futian District

Biotechnology
Health Care
1
14 May 2019 China, Shanghai

Tavotek Biotherapeutics

Biopharma
Biotechnology
Life Science
1
31 Jan 2019 United States, Lower Gwynedd Township

Health Care
Medical
Medical Device
1
18 Jan 2019 China, Shanghai
News
Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development

– Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development
– The financing includes a series-A1 round led by Apricot Capital, and a series-A2 round co-led by Loyal Valley Capital and Qiming Venture Partners.
– Medilink Therapeutics was established in 2020 by a sophisticated team of industrial veterans.
– Medilink has high ambitions for its ADC R&D to be globally competitive, and meet the needs of global patients in the future.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Apricot Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: